Discover and read the best of Twitter Threads about #jmuw
Most recents (1)
A thread on our recent analysis of WES, RNAseq, and clinical predictors of response to PD-1 ICB in metastatic melanoma patients led by @vanallenlab, Dirk Schadendorf, and Bastian Schilling with many others!
@NatureMedicine @DanaFarber @broadinstitute
nature.com/articles/s4159…
@NatureMedicine @DanaFarber @broadinstitute
nature.com/articles/s4159…
@VanAllenLab @NatureMedicine @DanaFarber @broadinstitute Our cohort was 144 metastatic melanoma patients who received PD-1 ICB. Overall response rate (CR or PR) was 38%; and subtypes were 86% cutaneous or occult melanoma, 7% acral, and 7% mucosal. Median follow-up was 30 months. 39% had BRAF mutations, 30% NRAS, and 17% NF1. [2/n] 
@VanAllenLab @NatureMedicine @DanaFarber @broadinstitute TMB was higher in responders vs. non-responders overall, as seen previously, but the effect is confounded by melanoma subtype; mucosal and acral melanomas have lower TMB and response rates. Stratified by subtype, the difference in TMB is no longer statistically significant. [3/n]
